| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 17 | 2023 | 1338 | 2.770 |
Why?
|
| Breast Neoplasms | 65 | 2024 | 16183 | 2.630 |
Why?
|
| Mass Screening | 12 | 2024 | 1545 | 2.510 |
Why?
|
| Selective Estrogen Receptor Modulators | 10 | 2018 | 128 | 1.990 |
Why?
|
| Mammography | 18 | 2024 | 1052 | 1.510 |
Why?
|
| Raloxifene Hydrochloride | 8 | 2015 | 46 | 1.210 |
Why?
|
| Aromatase Inhibitors | 4 | 2022 | 311 | 1.200 |
Why?
|
| Risk Reduction Behavior | 5 | 2017 | 209 | 1.140 |
Why?
|
| Carcinoma, Lobular | 5 | 2023 | 616 | 0.870 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2023 | 209 | 0.860 |
Why?
|
| Patient Participation | 6 | 2020 | 453 | 0.830 |
Why?
|
| Tamoxifen | 12 | 2022 | 875 | 0.810 |
Why?
|
| Hyperplasia | 7 | 2023 | 557 | 0.810 |
Why?
|
| Medical Oncology | 3 | 2023 | 1463 | 0.800 |
Why?
|
| Breast Carcinoma In Situ | 2 | 2020 | 17 | 0.780 |
Why?
|
| Breast Self-Examination | 2 | 2012 | 17 | 0.770 |
Why?
|
| Breast | 8 | 2021 | 1366 | 0.750 |
Why?
|
| Decision Making | 7 | 2018 | 1249 | 0.680 |
Why?
|
| Precancerous Conditions | 4 | 2023 | 1033 | 0.660 |
Why?
|
| Smokers | 1 | 2020 | 154 | 0.630 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 11 | 0.580 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 601 | 0.540 |
Why?
|
| Exercise | 4 | 2021 | 1206 | 0.540 |
Why?
|
| Female | 80 | 2024 | 148486 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 1231 | 0.510 |
Why?
|
| Risk Assessment | 15 | 2024 | 6752 | 0.500 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 999 | 0.500 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2023 | 1900 | 0.480 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 488 | 0.470 |
Why?
|
| Middle Aged | 55 | 2024 | 90030 | 0.450 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 318 | 0.440 |
Why?
|
| Awareness | 2 | 2012 | 114 | 0.430 |
Why?
|
| Breast Density | 3 | 2024 | 20 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 7779 | 0.420 |
Why?
|
| Insurance Coverage | 1 | 2014 | 274 | 0.400 |
Why?
|
| Humans | 83 | 2024 | 270033 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 2388 | 0.380 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 12019 | 0.360 |
Why?
|
| High-Intensity Interval Training | 2 | 2021 | 10 | 0.360 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2023 | 690 | 0.360 |
Why?
|
| Breast Diseases | 3 | 2020 | 200 | 0.360 |
Why?
|
| Adult | 40 | 2024 | 81689 | 0.340 |
Why?
|
| Risk Factors | 21 | 2023 | 17824 | 0.330 |
Why?
|
| Medicare | 1 | 2014 | 925 | 0.330 |
Why?
|
| Dietary Supplements | 2 | 2024 | 562 | 0.300 |
Why?
|
| Vaginal Smears | 4 | 2023 | 166 | 0.280 |
Why?
|
| Ultrasonography, Mammary | 6 | 2022 | 387 | 0.280 |
Why?
|
| Aged | 35 | 2024 | 73127 | 0.270 |
Why?
|
| Age Factors | 6 | 2018 | 5449 | 0.270 |
Why?
|
| Overweight | 2 | 2020 | 484 | 0.270 |
Why?
|
| Algorithms | 2 | 2016 | 3896 | 0.260 |
Why?
|
| Health Literacy | 2 | 2019 | 117 | 0.260 |
Why?
|
| Patient Compliance | 3 | 2019 | 676 | 0.250 |
Why?
|
| Volatile Organic Compounds | 1 | 2024 | 13 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2019 | 1229 | 0.240 |
Why?
|
| Cholecalciferol | 1 | 2024 | 49 | 0.230 |
Why?
|
| Breath Tests | 1 | 2024 | 192 | 0.230 |
Why?
|
| Counseling | 4 | 2023 | 381 | 0.230 |
Why?
|
| Cardiorespiratory Fitness | 2 | 2021 | 20 | 0.230 |
Why?
|
| Quality of Life | 2 | 2016 | 4772 | 0.230 |
Why?
|
| Perception | 4 | 2022 | 349 | 0.220 |
Why?
|
| Neoplasms | 5 | 2019 | 15902 | 0.220 |
Why?
|
| Biopsy, Large-Core Needle | 4 | 2023 | 139 | 0.220 |
Why?
|
| United States | 7 | 2020 | 15776 | 0.220 |
Why?
|
| Catechin | 2 | 2014 | 34 | 0.220 |
Why?
|
| Health Promotion | 1 | 2007 | 510 | 0.220 |
Why?
|
| Premenopause | 2 | 2024 | 138 | 0.220 |
Why?
|
| Family Practice | 1 | 2023 | 131 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 10382 | 0.210 |
Why?
|
| Nipple Discharge | 1 | 2022 | 8 | 0.210 |
Why?
|
| Cancer Survivors | 2 | 2020 | 744 | 0.210 |
Why?
|
| Anticarcinogenic Agents | 2 | 2001 | 368 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2018 | 1318 | 0.200 |
Why?
|
| Health Personnel | 3 | 2023 | 649 | 0.200 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 212 | 0.200 |
Why?
|
| Medical Overuse | 2 | 2018 | 51 | 0.190 |
Why?
|
| Risk | 6 | 2021 | 1937 | 0.190 |
Why?
|
| Vitamin D | 2 | 2024 | 261 | 0.190 |
Why?
|
| Primary Prevention | 2 | 2015 | 233 | 0.190 |
Why?
|
| Mastectomy | 4 | 2022 | 1553 | 0.190 |
Why?
|
| Celecoxib | 1 | 2020 | 198 | 0.170 |
Why?
|
| Resistance Training | 1 | 2019 | 39 | 0.160 |
Why?
|
| Postmenopause | 5 | 2019 | 377 | 0.160 |
Why?
|
| Comprehension | 1 | 2019 | 103 | 0.160 |
Why?
|
| Papanicolaou Test | 2 | 2017 | 116 | 0.160 |
Why?
|
| Device Removal | 1 | 2021 | 338 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 2646 | 0.160 |
Why?
|
| Obesity | 3 | 2020 | 2901 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2021 | 744 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 42 | 0.150 |
Why?
|
| CA-125 Antigen | 2 | 2024 | 228 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2020 | 402 | 0.150 |
Why?
|
| Health Behavior | 2 | 2015 | 600 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2018 | 372 | 0.150 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 14615 | 0.150 |
Why?
|
| Health Communication | 1 | 2018 | 36 | 0.150 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2017 | 3 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 83 | 0.150 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2017 | 16 | 0.150 |
Why?
|
| Incidence | 7 | 2018 | 5806 | 0.140 |
Why?
|
| Ultrasonography | 4 | 2024 | 1928 | 0.140 |
Why?
|
| Receptors, Estrogen | 4 | 2016 | 2158 | 0.140 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 166 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 114 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 788 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 516 | 0.140 |
Why?
|
| Endometrial Neoplasms | 3 | 2024 | 1388 | 0.140 |
Why?
|
| Breast Implants | 1 | 2021 | 375 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 7892 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 228 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2358 | 0.130 |
Why?
|
| Logistic Models | 7 | 2021 | 3438 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 15172 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 601 | 0.120 |
Why?
|
| Biomarkers | 2 | 2019 | 5046 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2018 | 266 | 0.120 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 30923 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 530 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 165 | 0.120 |
Why?
|
| Health Education | 1 | 2017 | 303 | 0.120 |
Why?
|
| Retrospective Studies | 12 | 2023 | 39736 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 5906 | 0.120 |
Why?
|
| Biopsy | 3 | 2018 | 3384 | 0.120 |
Why?
|
| North America | 1 | 2015 | 337 | 0.120 |
Why?
|
| Androstadienes | 1 | 2015 | 172 | 0.120 |
Why?
|
| Tea | 1 | 2014 | 46 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2019 | 1570 | 0.120 |
Why?
|
| Erotica | 1 | 2013 | 11 | 0.120 |
Why?
|
| Internet | 2 | 2017 | 689 | 0.110 |
Why?
|
| Mammaplasty | 1 | 2021 | 714 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 5773 | 0.110 |
Why?
|
| Cognition | 2 | 2010 | 968 | 0.110 |
Why?
|
| Libido | 1 | 2013 | 37 | 0.110 |
Why?
|
| Papilloma | 1 | 2013 | 86 | 0.110 |
Why?
|
| Patient Care Team | 2 | 2016 | 822 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 553 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1032 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4785 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 440 | 0.110 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2013 | 71 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 599 | 0.110 |
Why?
|
| Human papillomavirus 18 | 1 | 2012 | 42 | 0.110 |
Why?
|
| Russia | 1 | 2012 | 55 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 4944 | 0.100 |
Why?
|
| Receptors, Progesterone | 2 | 2016 | 1603 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1821 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2020 | 687 | 0.100 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 10695 | 0.100 |
Why?
|
| Video Recording | 1 | 2014 | 278 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2014 | 225 | 0.100 |
Why?
|
| Vaginal Neoplasms | 1 | 2012 | 152 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 617 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 1376 | 0.090 |
Why?
|
| India | 1 | 2012 | 312 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2012 | 255 | 0.090 |
Why?
|
| China | 1 | 2012 | 634 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 657 | 0.090 |
Why?
|
| Triazoles | 1 | 2015 | 628 | 0.090 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 530 | 0.090 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2010 | 34 | 0.090 |
Why?
|
| Nitriles | 1 | 2015 | 938 | 0.090 |
Why?
|
| Minority Health | 1 | 2009 | 16 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2017 | 2231 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1984 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2020 | 156 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1042 | 0.080 |
Why?
|
| Male | 9 | 2020 | 127917 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 347 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 1387 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 841 | 0.080 |
Why?
|
| Nomograms | 1 | 2010 | 312 | 0.080 |
Why?
|
| Prognosis | 6 | 2019 | 22451 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2020 | 2843 | 0.070 |
Why?
|
| Decision Trees | 1 | 2007 | 181 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2019 | 2586 | 0.070 |
Why?
|
| Image-Guided Biopsy | 2 | 2023 | 336 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2020 | 629 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3653 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2009 | 434 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 1299 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2015 | 1695 | 0.070 |
Why?
|
| Time Factors | 2 | 2018 | 12953 | 0.070 |
Why?
|
| Estrogens | 1 | 2010 | 808 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2021 | 5666 | 0.060 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 172 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 33691 | 0.060 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 110 | 0.060 |
Why?
|
| Survivors | 2 | 2013 | 1022 | 0.060 |
Why?
|
| Smoking | 1 | 2014 | 2548 | 0.060 |
Why?
|
| Body Weight | 2 | 2020 | 1306 | 0.060 |
Why?
|
| Psychometrics | 1 | 2009 | 969 | 0.060 |
Why?
|
| Brain | 2 | 2018 | 4210 | 0.060 |
Why?
|
| Case-Control Studies | 5 | 2017 | 6204 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2005 | 111 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 635 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2004 | 148 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2017 | 2296 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2005 | 313 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 2005 | 207 | 0.050 |
Why?
|
| Prospective Studies | 6 | 2020 | 13378 | 0.050 |
Why?
|
| Premedication | 1 | 2002 | 133 | 0.050 |
Why?
|
| Dissent and Disputes | 1 | 2022 | 40 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2020 | 675 | 0.050 |
Why?
|
| Medical Device Recalls | 1 | 2021 | 5 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2007 | 1185 | 0.050 |
Why?
|
| Silicone Gels | 1 | 2021 | 19 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 294 | 0.050 |
Why?
|
| Surface Properties | 1 | 2021 | 188 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 787 | 0.050 |
Why?
|
| Carcinoma | 1 | 2012 | 2607 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2020 | 30 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2021 | 191 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2023 | 636 | 0.040 |
Why?
|
| Texas | 3 | 2019 | 6430 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 3210 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 379 | 0.040 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 13996 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2019 | 2238 | 0.040 |
Why?
|
| Histones | 1 | 2007 | 1512 | 0.040 |
Why?
|
| Audiovisual Aids | 1 | 2019 | 39 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 118 | 0.040 |
Why?
|
| DNA Damage | 1 | 2007 | 1981 | 0.040 |
Why?
|
| Truth Disclosure | 1 | 2021 | 178 | 0.040 |
Why?
|
| Triage | 1 | 2021 | 256 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2006 | 1858 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 525 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2007 | 2165 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 5061 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 653 | 0.040 |
Why?
|
| Breast Implantation | 1 | 2021 | 222 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 748 | 0.040 |
Why?
|
| Pamphlets | 1 | 2018 | 34 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2021 | 293 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 618 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 103 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2018 | 129 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 5153 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2020 | 558 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 9040 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2018 | 120 | 0.040 |
Why?
|
| Culture | 1 | 2017 | 104 | 0.040 |
Why?
|
| Thromboembolism | 2 | 2010 | 150 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 245 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 389 | 0.030 |
Why?
|
| Observation | 1 | 2016 | 52 | 0.030 |
Why?
|
| Trust | 1 | 2017 | 109 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1236 | 0.030 |
Why?
|
| Probability | 2 | 2010 | 883 | 0.030 |
Why?
|
| Cataract | 2 | 2010 | 236 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2010 | 1145 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1087 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 1260 | 0.030 |
Why?
|
| Informed Consent | 1 | 2018 | 416 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 400 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 630 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 10258 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 3993 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 246 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 699 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 7883 | 0.030 |
Why?
|
| Registries | 2 | 2016 | 2205 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 155 | 0.030 |
Why?
|
| Arousal | 1 | 2013 | 128 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 4043 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 443 | 0.030 |
Why?
|
| Fractures, Bone | 2 | 2006 | 310 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1101 | 0.030 |
Why?
|
| Photomicrography | 1 | 2012 | 23 | 0.030 |
Why?
|
| Triglycerides | 1 | 2014 | 610 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 612 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2012 | 106 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 658 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 2650 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2010 | 40 | 0.020 |
Why?
|
| Emotions | 1 | 2013 | 560 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 311 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 87 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 224 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 188 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1320 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 424 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 729 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2009 | 178 | 0.020 |
Why?
|
| Women's Health | 1 | 2009 | 197 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 22134 | 0.020 |
Why?
|
| DNA Probes, HPV | 1 | 2007 | 12 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 66 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 1577 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4819 | 0.020 |
Why?
|
| Research Design | 2 | 2005 | 1569 | 0.020 |
Why?
|
| Patient Selection | 2 | 2005 | 2026 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2005 | 107 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1039 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1391 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2005 | 38 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1309 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 753 | 0.020 |
Why?
|
| Uterus | 1 | 2010 | 798 | 0.020 |
Why?
|
| Bias | 1 | 2005 | 214 | 0.020 |
Why?
|
| Thyroxine | 1 | 2005 | 114 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8668 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 4249 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2004 | 233 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 5585 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 232 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 713 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 778 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 1130 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 8107 | 0.010 |
Why?
|
| Fenretinide | 1 | 2002 | 100 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13946 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 15900 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2005 | 651 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 576 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16987 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 369 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 2590 | 0.010 |
Why?
|
| Prodrugs | 1 | 2002 | 226 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 16640 | 0.010 |
Why?
|
| Thrombosis | 1 | 2006 | 741 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9464 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 5099 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 2389 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 5309 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 4318 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 1057 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 32647 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 1957 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 6840 | 0.010 |
Why?
|
| Child | 1 | 2018 | 30466 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 12087 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 4646 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 4360 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 9288 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 3343 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 61714 | 0.000 |
Why?
|